No Data
Recursion Pharmaceuticals Is Maintained at Overweight by Keybanc
Recursion Pharmaceuticals Analyst Ratings
KeyBanc Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Cuts Target Price to $10
KeyBanc Lowers Price Target on Recursion Pharmaceuticals to $10 From $12, Keeps Overweight Rating
Recursion Pharmaceuticals Announces 2 Key Investigational Oncology Drugs Advancing To Clinical Trials, Targeting High Unmet Needs In Hematologic Malignancies, Small-Cell Lung Cancer, & More
Express News | Recursion Pharmaceuticals Inc - First Patient to Be Dosed in Phase 1 Excelerize Trial in Q1 2025